Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Webcast

Kezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care Conference


Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that Chris Kirk, Co-founder and Chief Executive Officer, will participate on the Cardiorenal Corporate Panel at the TD Cowen 44th Annual Health Care Conference. The panel will be held on Tuesday, March 5, 2024, at 10:30 a.m. ET.

A webcast of the panel discussion will be available on the "Events & Presentations" section of the Company's website at www.kezarlifesciences.com. Following the event, an archived webcast will be available on the Kezar website for 90 days.

About Kezar Life Sciences

Kezar Life Sciences is a clinical-stage biopharmaceutical company developing novel treatments for immune-mediated and oncologic disorders. Zetomipzomib, a selective immunoproteasome inhibitor, is currently being evaluated in a Phase 2b clinical trial for lupus nephritis and a Phase 2a clinical trial for autoimmune hepatitis. This product candidate also has the potential to address multiple chronic immune-mediated diseases. Kezar's oncology product candidate, KZR-261, targeting the Sec61 translocon and protein secretion pathway, is being evaluated in an open-label dose-escalation Phase 1 clinical trial to assess safety, tolerability and preliminary tumor activity in solid tumors. For more information, visit www.kezarlifesciences.com, and follow us on LinkedIn, Facebook, Twitter and Instagram.


These press releases may also interest you

at 10:40
Global Food Fortification Market is set to expand an expected CAGR of 2.7% until 2034 | Future Market Insights, Inc.
The food fortification market size is to be valued at US$ 106.7 billion by 2024. The market valuation is estimated to be US$ 286 billion by 2034, projected at a...

at 10:35
Probiotics in Animal Feed Market Size to Grow USD 5357.7 Million by 2030 at a CAGR of 4.2% | Valuates Reports
Probiotics in Animal Feed Market is Segmented by Type (Bacteria Source, Yeast Source), by Application (Cattle, Poultry, Swine, Aquaculture). The Global Probiotics in Animal Feed Market was valued at USD 3897.4 Million in 2023 and is anticipated to...

at 10:30
GenomOncology Introduces Expanded Support for Germline Testing in GO Pathology Workbench
GenomOncology (GO) revealed today an upgraded version of GO Pathology Workbench, their software platform for tertiary analysis and reporting of next generation sequencing (NGS) and other molecular testing results. This version includes expanded...

at 10:30
Cancer Biomarkers Market Worth $42.0 billion | MarketsandMarketstm
Cancer Biomarkers Market in terms of revenue was estimated to be worth $24.5 billion in 2024 and is poised to reach $42.0 billion by 2029, growing at a CAGR of 11.3% from 2024 to 2029 according to a new report by MarketsandMarketstm. Increasing...

at 10:30
Global Plant Stem Cell Skincare Product Market to reach a Valuation of US$ 353.9 million by 2034 | Future Market Insights, Inc.
Future Market Insights (FMI) predicts a surge in the plant stem cell skincare product market. This growth is primarily driven by rising consumer demand for multi-benefit skincare solutions. Consumers are increasingly seeking products that offer...

at 10:25
Cold Box Express, Inc. Introduces Refreshed Brand, New Website to Better Define Offering
Cold Box Express, Inc. (CBX) has announced a rebranding of both the company and its product the ClimateCratetm (formerly COLD BOX). While the corporate company name remains Cold Box Express, Inc., the evolution to CBX simplifies the logo and helps...

More news about Health...


News published on and distributed by: